RECRUITING

An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

Description

A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.

Conditions

Colorectal CancerCRC (Colorectal Cancer)Cancer Cachexia
Talk to us

Related Conditions:

Colorectal CancerCRC (Colorectal Cancer)Cancer Cachexia

Study Overview

On this page

Study Details

Study overview

A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.

A Phase 2, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants With Colorectal Cancer Who Have Cancer Cachexia

An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

Condition
Colorectal Cancer
Intervention / Treatment

-

Contacts and Locations

Laredo

NGM Clinical Study Site, Laredo, Texas, United States, 78041

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Documented active diagnosis of colorectal cancer.
  • 2. Cachexia defined by Fearon criteria of weight loss.
  • 3. Signed informed consent.
  • 1. Current active reversible causes of decreased food intake.
  • 2. Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization.
  • 3. Have cachexia caused by other reasons.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

NGM Biopharmaceuticals, Inc,

NGM Study Director, STUDY_DIRECTOR, NGM Biopharmaceuticals, Inc

Study Record Dates

2027-12